<DOC>
	<DOCNO>NCT01283321</DOCNO>
	<brief_summary>Heart surgery involve valve replacement often involve use heart-lung machine 90 minute , bleed tendency frequently see . Conventionally , platelet transfusion primary therapy treat bleed type procedure . More recently , perioperative supplementation purify fibrinogen ( RiaSTAP , CSL Behring ) show reduce bleed blood product use ( plasma platelet ) heart surgery . The objective trial demonstrate clinical equivalency economic utility use fibrinogen concentrate , RiaSTAP mitigation post-operative bleeding patient lieu platelet transfusion . Purified fibrinogen concentrate approve FDA , use treatment acute bleed episode patient low fibrinogen due hereditary cause ( e.g. , afibrinogenemia ) . Compared transfusion platelet may associate volume overload , bacterial/viral infection , immunological effect excess blood clotting , purify fibrinogen several advantage . First , contain liquid plasma allow low volume infusion . Several viral inactivation/reduction step use prepare fibrinogen concentrate , increase viral safety . No antibody white blood cell contain fibrinogen concentrate ; therefore transfusion reaction rare . Although platelet transfusion widely use heart surgery , randomize study endorse practice . In study , patient undergoing heart valve replacement randomize receive either platelet ( 1 unit ) transfusion fibrinogen concentrate ( 4g ) heparin anticoagulation reverse . Subjects treat evidence significant microvascular bleeding . Fifteen minute initial treatment , subject reevaluate bleeding . If bleeding continue , subject treat blood transfusion per institutional standard care . The primary endpoint study hemostatic condition surgical field 24-hour total blood product transfusion .</brief_summary>
	<brief_title>RiaSTAP v . Conventional Transfusion Patients Having Heart Valve Surgery</brief_title>
	<detailed_description>Platelet plasma transfusion remain mainstay hemostatic therapy perioperative bleeding . Several study indicate acquire fibrinogen deficiency primary cause bleed cardiac surgery . The aim study compare hematologica transfusion profile first-line fibrinogen replacement platelet transfusion post-cardiac surgical bleeding . In prospective randomize , open-lable study , 20 adult patient undergo valve replacement repair , fulfil preset visual bleeding scale ( 0=excellent hemostasis ; 1=oozing ; 2=moderate bleeding ; 3=severe bleed multiple bleeding site ) randomize 4 g fibrinogen 1 unit apheresis platelet transfusion . After initial randomized intervention , additional transfusion give presence bleeding ( &gt; 200 ml/hour ) accord institutional practie follow ; 1 apheresis platelet unit platelet count le 100 x 10^9 /L , 2 unit plasma international normalized ratio &gt; 1.6 , 10 unit cryoprecipitate fibrinogen level &lt; 200 mg/dL . Primary endpoint include hemostatic condition surgical field 24-hour hemostatic product usage . Hematologica data , clinical outcome , safety date collect 28th day postoperative visit .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>Willing able provide write informed consent Age &gt; 17 &lt; 86 year Patients undergo plan cardiopulmonary bypass ( CPB ) : 1. combine coronary artery bypass graft valve replacement/repair surgery 2. single valve replacement surgery 3. mitral valve repair surgery 3. double valve surgery ( aortic mitral ) Presence clinically relevant microvascular bleeding protamine administration ( hemostasis assessment score 23 ) Patients fulfill follow parameter prior study intervention : Body temperature &gt; 35.0°C Blood pH &gt; 7.2 Hb &gt; 7.0 mg/dL Activated clotting time ( ACT ) &lt; 155 second CPB time &gt; 60 minute Replacement aorta Planned valve replacement without median sternotomy Previous valve replacement surgery ( previous coronary artery bypass graft ( CABG ) acceptable ) History suspicion congenital acquire coagulation disorder hemophilia , von Willebrand disease , liver disease Hemodialysis dependent renal failure Liver dysfunction ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) increase ≥ 2fold upper limit local laboratory normal range ) Known allergy/anaphylaxis fibrinogen concentrate apheresis platelet unit Clopidogrel administration within 5 day surgery Coumadin ( warfarin ) administration within 5 day surgery Participation another clinical study 4 week precede surgery Any indication potential subject comprehend study restriction , procedure , consequence therein informed consent convincingly give Life expectancy le 48 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hemostasis</keyword>
	<keyword>Cardiopulmonary bypass ( heart-lung machine )</keyword>
	<keyword>Fibrinogen</keyword>
	<keyword>platelet</keyword>
</DOC>